My career began in cancer research, where I saw firsthand how lab discoveries can make a tangible difference for patients. I then worked at AstraZeneca developing new medicines for breast and ovarian cancer. It was exciting work, but I found myself wanting to zoom out and understand how the therapies I was researching got funded, developed, and delivered to patients. That curiosity led me to early-stage investing in biotech companies at IP Group. Now at SoftBank, I have the privilege of working with growth-stage companies and helping scale promising technologies.

Venture capital fills a crucial gap known as the “valley of death,” the stage between early research and commercialization, when many promising technologies falter. So VCs step in to identify the science, the ideas, and the people with the potential to become viable commercial products.

For early-stage companies, venture brings not only capital, but also expertise and mentorship. We help founders navigate scientific, regulatory, and operational challenges that come with bringing new technologies to the market.

Beyond technical rigor, my scientific background taught me to be comfortable with uncertainty. As an investor, I’ve come to understand the entire innovation cycle. Knowing that even good science can stumble helps me hedge risk. It guides my approach to building strong teams, allocating capital, and bringing in the right partners to tackle the inevitable obstacles along the way. 

I approach founders with humility and deep respect. Breakthrough science takes time, and I see our partnerships as multi-year journeys built on trust and transparency. 

In January 2024, I led our investment in Metsera, a biotech company developing the next wave of obesity medicines. It came out of research at Imperial College, my alma mater. The science was strong, but needed ample capital to fund clinical execution.

In November 2025, Pfizer acquired Metsera for $10 billion. It was an incredible outcome for shareholders, and a clear example of how venture funding, combined with the right timing and team, can bring groundbreaking science to the market.

I’m really passionate about building female investor communities. In 2022, together with some friends in the industry, I started Venture Women, a network specifically for female life sciences investors. We get together quarterly for relaxed, no-pressure events like going to a gig or having dinner together. It’s intentionally low-profile — you won’t find us on LinkedIn — but it’s become a great space for connection and support.